Generic Name: idelalisib
Drug Class: Targeted Therapy Medications
Company: Gilead Sciences
Approval Status: Approved
Generic Version Available: No
Zydelig is a PI3K kinase inhibitor approved for relapsed follicular lymphoma, relapsed chronic lymphocytic leukemia and relapsed small lymphocytic lymphoma.
Zydelig inhibits phosphatidylinositol-3-kinase (PI3K), an enzyme that is part of signaling pathways that play a role in cell growth and metabolism. It is active against PI3K on cancerous B cells, which grow out of control in people with leukemia and lymphoma.
A study of people with chronic lymphocytic leukemia showed that Zydelig slows disease progression. It received accelerated approval for follicular lymphoma and small lymphocytic lymphoma based on promising response rates in clinical trials.
Zydelig is taken as a twice-daily pill.
Common side effects include fatigue, diarrhea, nausea, fever, cough and pneumonia. Zydelig can cause depletion of white blood cells (neutropenia), which can lead to infections. Potentially serious side effects include liver toxicity, colon inflammation (colitis), intestinal damage, lung inflammation (pneumonitis) and severe skin reactions.
For More Info: https://www.zydelig.com/
Co-Pay Program Info: https://www.zydelig.com/resources-financial-support
Patient Assistance Program Info: https://www.zydelig.com/resources-financial-support
Last Reviewed: September 21, 2018